Immunocore (NASDAQ:IMCR) Stock Keeps “Buy” Rating at HC Wainwright

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright‘s price target suggests a potential upside of 219.69% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. began coverage on Immunocore in a report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price objective on the stock. Mizuho increased their price target on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.38.

Immunocore Stock Up 1.0%

NASDAQ IMCR traded up $0.30 during trading on Monday, reaching $31.28. 197,925 shares of the company’s stock were exchanged, compared to its average volume of 457,905. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a fifty-two week low of $27.50 and a fifty-two week high of $40.71. The company’s fifty day simple moving average is $32.82 and its 200-day simple moving average is $31.66. The firm has a market capitalization of $1.61 billion, a PE ratio of -84.54 and a beta of 0.81.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. Sell-side analysts predict that Immunocore will post 0.04 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its stake in shares of Immunocore by 30.9% in the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock valued at $17,919,000 after buying an additional 140,308 shares in the last quarter. Braidwell LP bought a new position in shares of Immunocore during the 2nd quarter worth about $16,552,000. Renaissance Technologies LLC boosted its position in shares of Immunocore by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 164,000 shares of the company’s stock valued at $4,945,000 after acquiring an additional 23,100 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Immunocore during the 2nd quarter valued at about $2,145,000. Finally, Stempoint Capital LP bought a new stake in Immunocore in the first quarter valued at about $1,916,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.